At Emcure Pharmaceuticals, we harness diverse and advanced API platform technologies to meet global healthcare demands. Our focus on innovation ensures high-quality solutions that cater to a wide range of therapeutic needs.
Chirality plays a crucial role in drug efficacy and safety. At Emcure, we specialize in asymmetric synthesis and chiral resolution techniques to produce enantiomerically pure APIs. These processes ensure enhanced therapeutic activity and reduced side effects for patients. For example, Amlodipine Besylate (Antihypertensive) was marketed as a racemic mixture. Emcure pioneered chiral technology to manufacture and market S-Amlodipine. Based on the success of S-amlodipine, Emcure further introduced 13 chiral products which were earlier sold as racemic compounds.
Anemia is a major health concern in India with more than 50% of children and women being affected. Iron products-based therapy is the only solution to address this concern. Emcure took up the onus by developing and marketing 5 iron products in the Indian market. Ferric carboxy maltose and Ferrous ascorbate are the Flag-ship products in this treatment regime. Iron-based drugs present a formidable challenge in the development and manufacturing of APIs and formulations.
AIDS is still a major health scare globally including India. Over a while, a large number of anti-HIV drugs have been approved and Emcure has emerged as a leader in antiretroviral API production. Our innovative processes ensure high-quality APIs that meet stringent regulatory requirements, improving accessibility to life-saving treatments. In this endeavour to produce cost-effective anti-HIV drugs, Emcure has developed and marketed many drugs including Atazanavir, Ritonavir, Tenofovir, Dolutegravir etc. Recently, Emcure obtained a Voluntary License to develop Gilead’s blockbuster drug Lenacapavir.
The development of Oncology drugs is associated with complex synthetic chemistry and specialized operations. In this category, Emcure has been successful in introducing drugs like Eribulin, Carmustine, Ironetecan, Melphalan, Busulphan etc.
For the treatment of patients suffering from Chronic Kidney Diseases (CKDs), Emcure has developed and marketed various phosphate-binding drugs such as Sevelamer HCl and carbonate, Sucroferric oxyhydroxide.
The API industry is moving from batch processes to continuous processes. In this domain, Flow chemistry has become an enabling technology. Emcure is in the process of scaling up this technology for various APIs. This approach ensures greater efficiency, scalability, and product quality while reducing waste and environmental impact.
Peptides as a class of drugs are finding unprecedented uses in various therapeutic indications. Emcure has mastered the technology of producing peptides with a large number of amino acid residues involving both solution and solid phase peptide chemistry. Products like Atosiban and Avaptidil have been successfully developed and marketed. Various other peptides are under development.
In recent years, Photochemistry has been a preferred choice for various chemical transformations that are otherwise difficult to achieve. Emcure’s use of this technology supports innovation in emerging therapeutic fields, delivering advanced solutions for unmet medical needs. The use of this technology to manufacture Dydrogesterone, a product used to prevent threatened/ recurrent miscarriage in pregnant women, is a major achievement in this area.